Clinical Trials Sponsored by Elemental Tai Chi

Total 399 results

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
Nanjing Chia-tai Tianqing Pharmaceutical

Completed

Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Xueli Cai

Recruiting

Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion (START)

Stroke | Thrombectomy | Tandem Occlusion

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Henan Provincial People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC (ALTER-L025)

Non-squamous Cell Non-Small Cell Lung Cancer

China
Jiangxi Provincial Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients (ALTER-E005)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms by Histologic Type | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Carcinoma, Squamous Cell | Esophageal Neoplasms | Esophageal Diseases | Neoplasms, Squamous Cell | Esophageal Squamous Cell Carcinoma

China
Trieu, Nguyen Thi, M.D.
Tran Minh Duc

Completed

Composition for Treating Spermatogenesis and Semen Disorders / FPT-20

Spermatogenesis and Semen Disorders

Vietnam
yi-chih HSU

Completed

Median Nerve Injury in US-guided Carpal Tunnel Injections

Carpal Tunnel Syndrome | Injury of Median Nerve Distal to Forearm

Taiwan
Bournemouth University
University of Southampton; National Institute for Health Research, United Kingdom and other collaborators

Completed

The TACIT Trial: TAi ChI for People With demenTia (TACIT)

Dementia | Accidental Falls

United Kingdom
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients

Non Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Qilu Hospital of Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer (ACDFNSNSCLC)

Non Small Cell Lung Cancer
Indiana University
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Alzheimer's Association and other collaborators

Recruiting

Lifestyle Interventions for the Treatment of Early Onset Alzheimer's Disease Study (LITES)

Alzheimer Disease, Early Onset

United States
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib or Penpulimab in Combination With RAI for DTC

Thyroid Cancer

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Nanfang Hospital of Southern Medical University
JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd

Unknown

Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy

Hepatitis B

China
Xin Cai

Not yet recruiting

Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion

Rectal Cancer | Recurrent

China
Yefeng Cai

Unknown

SouthErn China REgisTry for Stroke on Traditional Chinese Medicine (SECRETS-TCM)

Stroke | Transient Ischemic Attack | Cerebral Infarction | Subarachnoid Hemorrhage | Cerebral Hemorrhage

China
Cai Kailin

Unknown

A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery

Locally Advanced Gastric Cancer

China
CHA University
Medical AI Co., Ltd

Enrolling by invitation

ROMIAE (Rule-Out Acute Myocardial Infarction Using Artificial Intelligence Electrocardiogram Analysis) Trial (ROMIAE)

Myocardial Infarction or Chest Pain

Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zai Lab (Shanghai) Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. (CC-ANNIE)

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

China
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Lung Cancer Metastatic

China
The First People's Hospital of Lianyungang
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Lung Neoplasms | Anlotinib | Docetaxel | S-1 | Pemetrexed

China
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
First Affiliated Hospital Xi'an Jiaotong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (ALTER-H-004)

Hepatocellular Carcinoma | Anlotinib | TACE

China
Xiangya Hospital of Central South University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer

China
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
The Affiliated Hospital of Qingdao University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） (ACDFNSCLC)

Non Small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Lung Cancer | Lung Cancer Metastatic

China
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China
Wei Cai

Unknown

Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants

Preterm Infant

China
Cai Li

Unknown

Incidence and Predictive Factors of Intestinal Injury in Patients Undergoing Heart Valve Replacements

Injury of Other and Multiple Parts of Small Intestine

China
Nguyen Thi Thu Ha

Recruiting

Niche In CEsarean Scar Trial (NICEST)

Niche

Vietnam
Bin Cai

Recruiting

Cerebral Small Vessel Disease Registry Study

Cerebral Small Vessel Diseases

China
Bin Cai

Recruiting

CADASIL Registry Study

Cadasil

China
Cai Li

Completed

Reduction in MACbar of Sevoflurane by Dexmedetomidine in Children

Children
Cai Li

Completed

Effect of Remote Ischemic Preconditioning on Lung Injury After Pulmonary Resection

Lung Neoplasms

China
Cai Li

Completed

Limb Remote Ischemic Preconditioning Reduces Heart and Lung Injury After Abdominal Aortic Aneurysm Repair

Abdominal Aortic Aneurysm
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Biostar Pharmaceuticals...

Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Esophageal Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study

Refractory or Recurrent Neuroblastoma in Children
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (ALTER-L004)

Non Small Cell Lung Cancer

China
First Affiliated Hospital of Wenzhou Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Interstitial Lung Diseases

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M (ALTN-03)

Non Small Cell Lung Cancer

China

Clinical Trials Sponsored by Elemental Tai Chi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations